NTRBW

Nutriband Inc. Warrant

NTRBW, USA

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company has commercial development and clinical supply agreement with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

https://www.nutriband.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
NTRBW
stock
NTRBW

Bond Watch: Is Shenango Valley Water Co Preferred Security a good stock for dollar cost averaging - 2025 Fundamental Recap & Accurate Technical Buy Alerts baoquankhu1.vn

Read more →
NTRBW
stock
NTRBW

US Stocks Recap: Should you avoid CANF stock right now - 2025 Risk Factors & Weekly Stock Breakout Alerts baoquankhu1.vn

Read more →

Showing 2 of 10

Finn Analysis

(Last Updated 2025-10-31)

Health Score

Price to Book Ratio (P/B)

-

Very High

2.72

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-51.30 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-45.99 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-506.41 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.12

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Nutriband Inc. Warrant

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2021-04-30

EPS Actual

-0.0818

EPS Estimate

0

EPS Difference

-0.0818

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-10-31)

Deep Value
Weak Deep Value(2.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(0.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-10-31)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-10-31)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-10-31)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.